A Phase 1/2 Study of the Oral TRK Inhibitor LOXO101 (Larotrectinib) in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors
Phase of Trial: Phase I/II
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Larotrectinib (Primary) ; Larotrectinib (Primary)
- Indications CNS cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms SCOUT
- Sponsors Loxo Oncology
- 08 Sep 2017 Accroding to trial design presented at the 42nd European Society for Medical Oncology Congress, enrollment of phase II part of this study has began in April 2017.
- 08 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
- 12 Jul 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History